(Q35105819)

6 August 2017

title

TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trial (English)

1 reference

6 August 2017

main subject

phase II clinical trial

0 references

1 reference

18

Reinhard Dummer

1 reference

6 August 2017

Brigitte Dreno

1

1 reference

6 August 2017

Mirjana Urosevic-Maiwald

2

1 reference

6 August 2017

Youn Kim

3

1 reference

6 August 2017

Joan Guitart

4

1 reference

6 August 2017

Madeleine Duvic

5

1 reference

6 August 2017

Olivier Dereure

6

1 reference

6 August 2017

Amir Khammari

7

1 reference

6 August 2017

Anne-Chantal Knol

8

1 reference

6 August 2017

Anna Derbij

9

1 reference

6 August 2017

Monika Lusky

10

1 reference

6 August 2017

Isabelle Didillon

11

1 reference

6 August 2017

Anne-Marie Santoni

12

1 reference

6 August 2017

Bruce Acres

13

1 reference

6 August 2017

Vincent Bataille

14

1 reference

6 August 2017

Marie-Pierre Chenard

15

1 reference

6 August 2017

Pascal Bleuzen

16

1 reference

6 August 2017

Jean-Marc Limacher

17

1 reference

6 August 2017

publication date

24 February 2014

1 reference

6 August 2017

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

e83670

1 reference

Creative Commons Attribution 4.0 International

6 August 2017

copyright license

start time

24 February 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Primary cutaneous lymphomas: a reprisal.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

Immunopathogenesis and therapy of cutaneous T cell lymphoma

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

WHO-EORTC classification for cutaneous lymphomas

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

10 years experience of the Dermatology Life Quality Index (DLQI).

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

Interferon in the treatment of cutaneous T-cell lymphoma

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

Pathogenesis of cutaneous lymphomas

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933342

Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience

25 October 2018

1 reference

12 December 2020

Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification

1 reference

12 December 2020

Systemic rituximab in multifocal primary cutaneous follicle centre lymphoma

1 reference

12 December 2020

A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0083670

Identifiers

DOI

1 reference

6 August 2017

0 references

1 reference

6 August 2017

1 reference